Daiichi Sankyo, Inc.

Daiichi Sankyo Pharma Development is the product development arm of the U.S. organization, engaged in Clinical Development, Translational Medicine & Clinical Pharmacology, Regulatory Affairs & Risk Management, Informatics & Knowledge Management, Biostatistics and Data Operations and Development Research. We conduct clinical studies and expedite product registrations for the United States and Europe, and collaborate with our Tokyo parent company on all of our global product development projects as well.We are led by a group of highly experienced pharmaceutical executives who have gained broad experience at some of the world's leading pharmaceutical companies. In addition, we have a.significant number of senior staff from Japan to assist in and coordinate our global development activities. Along with our staff of about 200 employees, we utilize outsourcing strategies for.additional functional support. One such example is our partnership with MDS Pharma Services to establish the company's first collaborative clinical pharmacology unit. The unit is located in New Jersey and focuses on the evaluation of novel treatments for diabetes and lipid disorders.
Daiichi Sankyo, Inc. has just completed the integration of its two legacy companies that resulted in a new R&D organization -- including new processes and improved decision-making systems aimed at speeding global development.

Contact Details: Two Hilton Court Parsippany New Jersey 07054 United States of America Tel: 973 359 2600 Fax: 973 359 2645 Email: smallbusinessplan@daiichisankyo-us.com WWW: www.sankyopharma.com/

Loading...

Press Releases on Daiichi Sankyo, Inc.:
New Updates to AHA/ACC/SCAI Clinical Guidelines Recommend Treatment with Effient(R) for Patients with Acute Coronary Syndromes Managed with PCI	18th November, 2009	Eli Lilly and Company	PARSIPPANY, N.J. and INDIANAPOLIS, Nov. 18 /PRNewswire-FirstCall/ -- Effient® (prasugrel) tablets, a new antiplatelet medicine, was added as a treatment option in two clinical guideline updates: one
Effient(R) Exhibited Greater Antiplatelet Activity than High Dose Clopidogrel in Type 2 Diabetes Mellitus Patients with Coronary Artery Disease	15th November, 2009	Eli Lilly and Company	ORLANDO, Fla., Nov. 15 /PRNewswire-FirstCall/ -- Results from a new study showed patients with type 2 diabetes mellitus who also had coronary artery disease (CAD) and received a 60 mg loading dose and
Welchol(R) (colesevelam HCl) Receives FDA Approval to Lower LDL Cholesterol in Pediatric Patients with Heterozygous Familial Hypercholesterolemia	7th October, 2009	Daiichi Sankyo, Inc.	-- improve glycemic control in adults with type 2 diabetes mellitus Important Limitations of Use -- Welchol should not be used for the treatment of type 1 diabetes or for the
Survivors of Heart Events: What Does it Take to Get Back to Living?	22nd September, 2009	Eli Lilly and Company	-- 93% of patients who feel they had been given a second chance in life viewed it as an opportunity to do things better. -- Only 17% strongly agreed that they were worried about
Daiichi Sankyo and Lilly Receive U.S. FDA Approval for Effient(TM)	10th July, 2009	Eli Lilly and Company	PARSIPPANY, N.J. and INDIANAPOLIS, July 10 /PRNewswire-FirstCall/ -- Daiichi Sankyo, Inc. and Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA)

BioNews Results for Daiichi Sankyo, Inc.:
Nuvo Research, Ranbaxy signs deal to market Oxoferin in Asian countries	PharmaBiz:  Nov 13 2009 12:12PM Matching: daiichi sankyo inc
Exelixis Announces November 18 Webcast of Presentation at	Business Wire via MSN Money:  Nov 13 2009 1:44PM Matching: daiichi sankyo inc
Exelixis Announces November 18 Webcast of Presentation at Lazard's 6th Annual Healthcare Conference	Pharma Live:  Nov 13 2009 9:38PM Matching: daiichi sankyo inc
Exelixis Announces November 18 Webcast of Presentation at Lazards 6th Annual Healthcare Conference	Earthtimes.org:  Nov 13 2009 2:02PM Matching: daiichi sankyo inc
Exelixis Announces November 18 Webcast of Presentation at Lazard's 6th Annual Healthcare Conference	Forbes.com:  Nov 13 2009 1:46PM Matching: daiichi sankyo inc
Promote your company here: BioNewsCast - Press Release Distribution	→View more Daiichi Sankyo, Inc. news.

Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.

This page has been viewed 254 times since April 2007, the link to the organisation's website has been followed 46 times

Search for more companies in Parsippany

Search for more companies in New Jersey

This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.
BioPortfolio search results for Daiichi Sankyo, Inc.